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Objectives: To characterize the effects of CYP2B6 polymorphisms, diurnal variation and demographic factors on
nevirapine pharmacokinetics in African children.
Methods: Non-linear mixed-effects modelling conducted in NONMEM 7.3 described nevirapine plasma concen-
tration–time data from 414 children aged 0.3–15 years.
Results: Nevirapine pharmacokinetics was best described using a one-compartment disposition model with elim-
ination through a well-stirred liver model accounting for a first-pass effect and transit-compartment absorption.
Intrinsic clearance was affected by diurnal variation (characterized using a cosine function with peak amplitude
29% at 12 noon) and CYP2B6 metabolizer status [extensive metabolizer (EM) 516GG|983TT, reference; intermedi-
ate metabolizer (IM) 516GT|983TT or 516GG|983TC, 17% lower; slow metabolizer (SM) 516TT|983TT or
516GT|983TC, 50% lower; ultra-slow metabolizer (USM) 516GG|983CC, 68% lower]. Age was found to affect
pre-hepatic bioavailability: 31.7% lower at birth and increasing exponentially. Median (90% CI) evening Cmin values
in the different metabolizer groups were 5.01 (3.01–7.47), 6.55 (3.65–13.32), 11.59 (5.44–22.71) and 12.32
(12.32–27.25) mg/L, respectively. Evening Cmin values were ,3 mg/L in 43% of EM weighing ,6 kg and 26% of
IM weighing,6 kg, while 73% of SM and 88% of USM in all weight-bands had evening Cmin values.8 mg/L. Cmin
was not markedly affected by administration time, but was altered by unequal splitting of the daily dose.
Conclusions: Diurnal variation does not greatly affect nevirapine exposure. However, when daily doses cannot be
split equally, the larger dose should be given in the morning. To achieve homogeneous exposures, nevirapine doses
for SM and USM should be reduced by 50%, and children weighing,6 kg with EM or IM metabolizer status should
receive the same dose as children weighing 6–10 kg.
Introduction
Nevirapine was the first NNRTI available in low-income countries
in a generic paediatric fixed-dose combination (FDC) tablet. This
contributed to substantial cost reductions and improved the feasi-
bility of treating HIV-infected children, and nevirapine is still widely
used in resource-limited settings.1 – 4 Nevirapine has several
advantageous characteristics: it has fewer drug interactions
than PIs, it does not cause adverse CNS events when compared
with efavirenz, and its bioavailability is not affected by food.5
Despite its high potency, nevirapine has a low genetic barrier
for mutations and suboptimal drug exposures increase the risks
of developing drug resistance and treatment failure.6,7 Several
studies have reported highly variable nevirapine concentrations,
with levels ,3 mg/L among children in the lower paediatric
weight-bands when dosed according to WHO guidelines, increas-
ing the risk of virological failure.1,2,8 – 12 Nevirapine concentrations
.8 mg/L, on the other hand, were associated with an increased
risk of treatment discontinuation due to adverse events among
adults.7 However, paediatric studies quantifying nevirapine phar-
macokinetic variability due to different sources and suggesting
optimization of current dosing remain limited.8,13,14
Nevirapine has a complex metabolism mediated mainly by
CYP3A4- and CYP2B6-coded enzymes.15 SNPs present in CYP2B6
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(516G.T and 983T.C) were identified as the main source of
nevirapine variability in adults,16 – 18 as for efavirenz.4,18,19 The
prevalence of 516G.T loss of function (LOF) polymorphisms
differs between populations and is particularly high in black
Africans, whereas 983T.C variants are not observed among
Caucasians.4,18,19 In our previous investigation of efavirenz
pharmacokinetics in African children, we showed that extensive
metabolizers (EM; CYP2B6 516GG|983TT genotype) are at higher
risk of developing subtherapeutic efavirenz concentrations.20 A
similar investigation of differences in nevirapine exposures
between various metabolizer groups when dosed by weight-band
according to current WHO guidelines has not yet been conducted
in children. CYP2B6 expression may be further modified by
polymorphisms in genes coding nuclear receptors CAR (NR1|3)
and PXR (NR1|2),21,22 although this has not been proved for
nevirapine.23
The effect of the CYP3A4 pathway on nevirapine pharmacokin-
etics is less studied. Although not confirmed for nevirapine, sys-
temic exposures of CYP3A substrates have been shown to be
altered by SNPs rs35599367 (CYP3A4*22)24,25 and rs776746
(CYP3A5*1).26,27 Additionally, CYP3A activity exhibits diurnal vari-
ation, with nevirapine clearance rates increasing during the day
and reducing at night.28,29 Differences between morning (AM)
and evening (PM) nevirapine trough concentrations (Cmin) have
been previously reported30 and may relate to diurnal variation in
the CYP3A-mediated effects on pharmacokinetics.
The aim of this analysis was: (i) to model the steady-state
population pharmacokinetics of nevirapine in the largest cohort
of African children studied so far; (ii) to quantify demographic
and genotypic effects on nevirapine disposition; (iii) to character-
ize the effect of diurnal variation on nevirapine exposures under
various dosing scenarios; and (iv) to propose optimal dosing strat-
egies for this population.
Methods
In this analysis, sparsely sampled data from the CHAPAS-3 trial (Children
with HIV in Africa—Pharmacokinetics and Adherence of Simple
Antiretroviral Regimens)31 was enriched with intensive data from an earl-
ier pharmacokinetic sub-study1 (part of CHAPAS-1).32 Both studies were
conducted in African children from Uganda and Zambia, as briefly
described below.
CHAPAS-1
The trial evaluated dosing of, and adherence to, new paediatric FDC
tablets: Triomune Baby (50 mg nevirapine, 6 mg stavudine and 30 mg
lamivudine) and Junior (100 mg nevirapine, 12 mg stavudine and 60 mg
lamivudine) in children ,14 years dosed twice daily according to WHO
2006 guidelines.33 When the daily dose could not be split equally, the lar-
ger dose was given at night.
Children in the pharmacokinetic sub-study were sampled on one occa-
sion at least 4 weeks after starting treatment. Samples were taken imme-
diately prior to giving the morning dose and 1, 2, 4, 6, 8 and 12 h
afterwards. The time of the preceding evening dose was assumed to be
12 h before the morning dose. Samples were stored and assayed using
ultra HPLC with UV detection at the Department of Pharmacy of the
Radboud University Medical Centre, Nijmegen, The Netherlands. The
method was linear over the range of 0.1–10 mg/L. The average intra-assay
and inter-assay coefficients of variation (CV) and relative error (RE) were
2.9%, 2.4% and 97%, respectively.34
CHAPAS-3
Pharmacokinetics, toxicity, acceptability, adherence and virological efficacy
were compared between three first-line antiretroviral regimens in children
13 years or younger.31 Depending on treatment allocation, patients received:
Triomune Baby, Triomune Junior, Duovir-N Baby (50 mg nevirapine, 60 mg
zidovudine and 30 mg lamivudine) or nevirapine (100 mg)—all paediatric
formulations; or Duovir-N (200 mg nevirapine, 300 mg zidovudine and
200 mg lamivudine) or Triomune30 (200 mg nevirapine, 30 mg stavudine
and 150 mg lamivudine), formulated for adults. Nevirapine-based regimens
were dosed twice daily according to WHO 2010 guidelines.35 When the daily
dose could not be split equally, the larger dose was given in the morning.
Children on nevirapine were sampled during clinic visits at week 6, week
36 and every 24 weeks thereafter until the end of the study; at each visit
two samples were taken at least 2 h apart. The self-reported times of the
morning and penultimate doses were recorded. Samples were stored and
analysed by LC-tandem MS at the Division of Clinical Pharmacology,
University of Cape Town, South Africa. The method was linear over the
range of 0.0195–20 mg/L. The average intra-assay and inter-assay CV
and RE were 2.9%, 2.4% and 97%, respectively.
Genotyping
Genotyping was performed only on patients from CHAPAS-3 by allelic
discrimination real-time PCR assay on a DNA Engine Chromo4 system
(Bio-RadLaboratories, Inc.,Hercules,CA,USA).ThePCRprotocol involvedanini-
tialdenaturationstepat958Cfor15 min, followedby50cyclesofamplification
at 958C for 15 s and final annealing at 608C for 1 min. TaqManw Genotyping
Master Mix and assays for CYP2B6 516G.T (rs3745274; ID: C_7817765_60),
CYP2B6 983T.C (rs28399499; ID: C_60732328_20), CYP2B6 15582C.T
(rs4803419; ID: C_7817764_10), CYP3A4*22 (rs35599367,
C__59013445_10), CYP3A5 6986G.A (rs776746, C__59013445_10), NR1I3
(rs3003596, C__16194070_10 and rs2307424, C__25746794_20), NR1I2
63396C.T (rs2472677, C__26079845_10), and ABCC10 (rs2125739,
C__16173668_10) were obtained from Life Technologies Ltd (Paisley, UK).
Opticon Monitorw version 3.1 (Bio-Rad Laboratories) was used to obtain allelic
discrimination plots and make allele calls.
The distribution of the genotypes was tested for Hardy–Weinberg equi-
librium using the exact test in the R ‘genetics’ package.
Population pharmacokinetic analysis
Model building
The steady-state pharmacokinetics of nevirapine was analysed using non-
linear mixed-effects modelling with NONMEM 7.336 and the first-order
conditional estimation method with interaction. PsN 4.4.0, Pirana and
Xpose were used to facilitate modelling and for model diagnostics.37
Model building was conducted starting with intensive pharmacokinetic
data from CHAPAS-1 followed by sparse data from CHAPAS-3.38 The step-
wise process was guided by differences in the NONMEM objective function
value (OFV; proportional to 22 log-likelihood), inspection of goodness-
of-fit (GOF) plots and visual predictive checks (VPCs), biological plausibility
and clinical relevance. OFV drops .3.84 between two hierarchical models
after adding one parameter were considered a significant improvement
(P≤0.05, x2-distribution, df¼1). The stability and robustness of the final
model, together with the precision of parameter estimates, was evaluated
using non-parametric bootstrap (n¼50, due to long model run times).
The model-derived empirical Bayesian estimates for the individual
parameters were used to predict morning and evening Cmin and AUC0 –
12 (area under the concentration–time curve between dosing events) at
steady state for each sampling occasion and patient.
Structural model
One-, two- and three-compartment disposition models with first-
order absorption and elimination were tested, as well as delayed and
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transit-compartment39 absorption. A semi-mechanistic well-stirred
hepatic extraction model was tested for elimination, as in Gordi et al.40
This hepatic model assumed the following parameters: nevirapine
fraction unbound in plasma (fu) 40%,
41 hepatic plasma flow (QH) 50 L/h
42
and liver volume (VH) 1 L
40 for a typical 70 kg individual (allometrically
scaled).
Between-subject variability (BSV) and between-occasion variability
(BOV) were tested on all pharmacokinetic parameters assuming log-
normal distribution. Residual unexplained variability (RUV) was described
using a combined proportional and additive structure. We excluded from
the analysis data with uncertain dosage history and nevirapine concentra-
tions below the limit of quantification (BLQ), presumed to be due to non-
compliance38 (confirmed by undetectable concentrations of the compan-
ion antiretroviral drugs). Further implausible outliers were identified using
visual checks and excluded based on conditional weighted residuals
(|CWRESI|.3).
Covariate effects
Allometric scaling was added to the model at an early stage (before cov-
ariate testing), as suggested by Anderson and Holford,43 and applied to all
clearance and volume parameters. For intrinsic clearance (CLint) and pre-
hepatic bioavailability (FpreH) we tested the effect of age using a power,
hockey-stick, exponential or sigmoidal function with/without Hill coeffi-
cient models.43 The effect of diurnal variations was investigated using
step or cosine functions.29 Besides weight and age, the other covariates
tested were: study site, NRTI treatment backbone, sex, weight-for-
age Z-score (WAZ), height-for-age Z-score (HAZ) and formulation.
Pharmacogenetic effects were tested as individual SNPs (rs3745274,
rs28399499, rs4803419, rs35599367, rs776746, rs3003596, rs2307424,
rs2472677, rs2125739) and as metabolizer status determined by SNPs
516G.T and 983T.C [EM, genotype 516GG|983TT; intermediate metabol-
izer (IM), single variant allele (516GT|983TT or 516GG|983TC); slow metabol-
izer (SM), two variant alleles (516TT|983CC or 516GT|983TC); ultra-slow
metabolizer (USM), 983CC irrespective of 516G.T genotype].
Mixture modelling with frequencies fixed to those observed in the study
population was used to impute missing genotypes (predominantly in
CHAPAS-1).44 Proportionality and correction factors were applied on RUV
to test for differences between the assays and laboratories used.
Simulations
For the simulation (conducted with NONMEM 7.3), the demographics of
the 414 patients (weight 3.5–29.6 kg) from the original analysis were
used and enriched with 116 records of individuals weighing 20–35 kg
from CDC Growth Charts (age and corresponding median weight
used).45 The final model was used to simulate exposures after nevirapine
administration under various dosing scenarios and assuming 3–8 mg/L as
the therapeutic range for nevirapine.46 Each in silico patient was resimu-
lated 100 times, changing their metabolizer status according to the pro-
portions in the study population, which ensured the same distribution in
each weight-band. The effect of drug intake time (6:00, 7:00, 8:00, 9:00
AM/PM) and dose-splitting strategies (AM/PM D1:100/50 mg, D2:75/
75 mg, D3:50/100 mg) was studied in a single patient (0.44 years,
7.2 kg, IM) simulated 1000 times. To avoid generating implausibly extreme
values, the maximum variability for each random effect was limited to 3
standard deviations. Data analysis and plot generation was performed
using R.47
Results
Demographic characteristics and samples
This analysis included 3305 samples (539 in intensive and 2766 in
sparse pharmacokinetic profiles) from 414 African children (78
CHAPAS-1, 330 CHAPAS-3, 6 in both). Baseline demographic char-
acteristics are presented in Table 1; 246 samples were excluded
from the analysis (111 due to unclear dosage history, 87 outliers
and 48 BLQ). Genotypes were available for 324 children (Table S1,
available as Supplementary data at JAC Online); CYP2B6 metabol-
izer groups were 33.1% EM, 44.6% IM, 21.7% SM and 0.6% USM
(Table 2); the mixture-model allocation for the remaining 96 indi-
viduals was 41.7% EM, 49.0% IM and 9.4% SM. All tested geno-
types were in Hardy–Weinberg equilibrium (Table S1).
Population pharmacokinetics
Nevirapine pharmacokinetics were best described using one-
compartment disposition, absorption through transit compartments
Table 1. Demographic characteristics
Characteristic CHAPAS-1 CHAPAS-3 Combined
No. of children 84 336 414
No. of samples included 539 2766 3305
No. of samples excluded (BLQ) 8 (0) 238 (48) 246a
No. of sampling occasions, n or median (range) 1 3 (1–7) 3 (1–8)
Age (years)b, median (range) 6.2 (0.4–15.0) 2.6 (0.3–12.2) 2.92 (0.3–15.0)
Weight (kg)b, median (range) 15.75 (3.5–29.0) 11.5 (4.9–29.6) 12.2 (3.5–29.6)
WAZ, median (range) 21.1 (24.2–2.0) 21.7 (27.2–1.2) 21.5 (27.2–2.0)
Male/female, n/n 52/32 177/159 80/89
NRTI, n
abacavir 0 115 115
stavudine 84 107 191
zidovudine 0 114 114
Six patients rolled over from CHAPAS-1 to CHAPAS-3; all patients were black Africans.
aSamples excluded from the analysis: unclear dosage history, 111; implausible (visual check confirmed by |CWRES|.3), 87; and BLQ confirmed by
undetectable levels of the companion drugs, 48.
bBaseline values.
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and elimination using the semi-physiological model with first-
pass hepatic extraction (Figure 1 and Appendix S1). The final
model parameters were estimated relative to pre-hepatic bio-
availability (FpreH, with typical value fixed to 1) and are presented
in Table 3. All parameter estimates were found to be reasonably
robust and adequate model fit was confirmed through GOF and
VPC plots, which showed adequate fit of our model to the ana-
lysed data (Figures S1 and S2).
Implementing the well-stirred liver model decreased OFV by 42,
without adding extra parameters. The model was parameterized
with CLint following a circadian rhythm expressed through oscilla-
tions of the cosine function with zenith around 12 noon and amp-
litude of 29% (DOFV¼291, df¼2, P,0.001) (Figure 2). The
model identified distinct pre-hepatic (FpreH) and hepatic compo-
nents (FH) of bioavailability, since changes in liver activity mechan-
istically affected also FH. The reference value of FpreH was fixed to 1,
and BSV and BOV were estimated. Including the diurnal effect
reduced BSV in CLint by 34% and BOV in FpreH by 41%. More details
on the model implementation, including formulae explaining the
relationship between model parameters, are presented in
Appendix S1.
After applying allometric scaling to account for the effect of
body size, and including diurnal effects and first-pass metabolism,
the most significant covariate was the metabolizer status on CLint
determined by CYP2B6 516G.T|983T.C genotype (DOFV¼2217,
df¼3, P,0.001), explaining 85% of remaining BSV in CLint. Using
six rather than four 516G.T|983T.C SNP-vector metabolizer
groups20 reduced OFV by only 5 points (df¼2, P¼0.08) and was
therefore not used.
Our data did not support a maturation effect on CLint, but we
identified age-driven differences in FpreH, which were described
using an exponential model [Equation (7) in Appendix S1]. FpreH at
birth was estimated as 58.3% of the value in older children (refer-
ence fixed to 100%), 90% of FpreH was reached by age of
3.3 years and the half-life of the process was 1.55 years (Figure 3).
The model estimated that an average child weighing 14.5 kg
and aged 4.1 years would have FpreH¼93% and their values of
oral clearance (CLoral, see Appendix S1 and Table S2) were
1.31 L/h EM (reference), 1.09 L/h IM (17% lower), 0.66 L/h SM
(50% lower) and 0.42 L/h USM (68% lower). A summary of the
individual exposures in children from the CHAPAS-3 trial dosed
according to WHO 2010 guidelines35 is presented in Table 2,
split by metabolizer genotype.
Higher uncertainty related to unobserved intake time (for all
sparse data and pre-dose samples in intensive data) was
accounted for by scaling factors (proportional model) on RUV and
BOV FpreH, which were found to be respectively 1.56 and 1.54 times
larger than in pharmacokinetic samples after observed intake.
No other covariates were identified as significant. The remain-
ing stochastic variability in clearance and bioavailability was low
(BSV CLint 21.4%, BSV FpreH 18.7% and BOV FpreH 17%), but absorp-
tion parameters (where no covariates improved model fit)
remained highly variable [BOV absorption rate constant (Ka)
44.9%, BOV absorption mean transit time (MTT) 199.7%].
Simulations
Simulations were conducted to compare average CminAM and
CminPM in weight-bands of African children divided into metabol-
izer groups and dosed following WHO 2010 recommendations.35 Ta
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Average CminAM and CminPM in weight-bands .6 kg were .3 mg/L
for most simulated individuals regardless of metabolizer status
(Figure 4a). In contrast, .25% of children in the lowest weight-
band (4 –6 kg) had CminPM below the efficacy threshold
(Figure 4b); this effect was driven mostly by EM and IM (43%
and 26% ,3 mg/L, respectively).
Given the detected diurnal variation in nevirapine CLint, we
evaluated the effect of administration time (see the Methods
Dose
Transit Absorption
Ka Liver
Central
QH/Vc
(QH·EH)/VH = CLH/VH
QH·(1–EH)/VH
Vc
VH
Figure 1. Compartmental structure of the nevirapine pharmacokinetic model. CLH, hepatic clearance; EH, hepatic extraction; Ka, absorption rate
constant; QH, hepatic plasma flow; VH, volume of the liver; VC, volume of the central compartment. The model parameters and presented relations
are explained in detail in Appendix S1.
Table 3. Final parameter estimates (5th–95th percentile)a
Parameter Typical values Variability (%)b
CLint
EM (L/h) 3.27 (3.00–3.69) BSV CLint: 21.40 (20.08–32.46)
IM (L/h) 2.72 (2.27–2.94)
SM (L/h) 1.65 (1.47–1.89)
USM (L/h) 1.04 (0.87–1.38)
AMP (%) 29.2 (27.7–45.2)
SHIFT (h) 212.30 (213.32 to 210.38)
VC (L) 21.92 (20.24–26.23)
FpreH
older childrenc 1 (fixed) BSV FpreH: 18.72 (6.59–20.66)
at birth (%) 58.30 (50.48–68.24) BOV FpreH: 17.02 (16.12–20.87)
t1/2 (years) 1.54 (1.47–2.58)
Increased BOV FpreH for unobserved intake 1.54 (1.20–1.65)
MTT (h) 0.56 (0.49–0.70) BOV MTT: 199.73 (177.23–217.70)
Ka (1/h) 0.84 (0.67–1.12) BOV Ka: 44.91 (31.32–50.46)
NTRANS (number) 3 (fixed)
Additive error (mg/L) 0.32 (0.21–0.38)
Proportional error (%) 5.26 (4.26–6.18)
Increased error for sparse data 1.56 (1.49–1.81)
CLint, intrinsic clearance; AMP, amplitude of cosine function; SHIFT, shift in the zenith of cosine function from midnight; VC, volume of central
compartment; FpreH, pre-hepatic bioavailability; NTRANS, number of transit compartments (in the implementation of Savic et al.
39 this would be
NN¼2); MTT, absorption mean transit time; Ka, absorption rate constant; BSV, between-subject variability; BOV, between-occasion variability.
Final parameter estimates are typical population values estimated by the model. All clearance and volume parameters scaled allometrically to the
median weight of 14.5 kg.
The number of transit compartments was first estimated and then fixed during the covariate analysis in order to improve model stability. The number
was then re-estimated in the final model and proved not to be different from that previously fixed. The equations explaining the relation between pre-
sented parameters can be found in Appendix S1.
aEstimated from non-parametric bootstrap (n¼50) of the final model.
bExpressed as approximate %CV on SD scale (
p
ETA×100).
cOlder children refers to individuals where no further age-driven increase in bioavailability can be observed (Figure 3).
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section) on average morning and evening exposures. The changes
in median concentration depending on administration time and
differences in systemic drug exposures are presented in
Figure S3. Depending on administration time, the ratios of morn-
ing/evening exposures varied between 1.09–1.15 for Cmin and
1.03–1.07 for AUC0 – 12, differences that are unlikely to be clinically
significant.
Use of some nevirapine FDCs can lead to unequal splitting of
the advised daily dose between morning and evening intakes.
Simulation results showed that ratios between simulated median
CminAM/PM for tested dose-splitting strategies (see the Methods
section) were: D1 (larger morning) 0.93, D2 (equal) 1.13 and D3
(larger evening) 1.41; and AUC0 – 12 0.90, 1.04 and 1.22, respect-
ively (Figure S4).
Discussion
We present the largest investigation to date of nevirapine pharma-
cogenetics, the first report of the effect of 983CC homozygosity on
nevirapine pharmacokinetics and the first study in children to
quantify the combined effect of CYP2B6 516G.T|983T.C. Our
analysis is also the first to date to characterize the diurnal variation
in nevirapine clearance through population pharmacokinetic mod-
elling and to evaluate the effect of this phenomenon on systemic
drug exposures through simulations.
The main predictor of nevirapine clearance in our cohort of African
children was the combined effect of the CYP2B6 516G.T|983T.C
genotype. Oral clearance estimated by our model before adjusting
for the CYP2B6-SNPs was 3.8 L/h, comparable to the 3.93 L/h
reported previously in children13 (both scaled up to 70 kg) and the
2.82–3.97 L/h found in adults.16,17,38,48–53 Comparing the CYP2B6
516G.T|983T.C effect with other reports is problematic, since
our study is the first to use this categorization with four metabolizer
subgroups for nevirapine, although it has been extensively applied to
efavirenz.20,54 The 50% lower nevirapine clearance we detected for
SM is greater than the 30%–37% drop previously reported for
516TT versus 516GG.8,14,16,17,55,56 Similar to efavirenz,18,20 the effect
of CYP2B6 983CC (recessive homozygosity) on nevirapine pharmaco-
kinetics is of greater magnitude than that of 516TT (68% versus 50%
drop). Unsurprisingly, nevirapine clearance is affected to a lesser
degree by CYP2B6 polymorphisms than efavirenz in the same popu-
lation.20 This can be explained by a different contribution of the
CYP3A4 pathway to the metabolism of these drugs.57
Diurnal variation has been previously documented for several
CYP3A4 substrates,58,59 consistently revealing increased clearance
rates during the day as compared with during the night.28,60,61
Our study replicated those findings and detected significantly higher
nevirapine clearance during the day, with a maximum at midday.
The estimated amplitude of the diurnal variation is somewhat larger
than previous reports in CYP3A4 probes.28,60 This could be due to the
considerable contribution of CYP2B6 enzymes to nevirapine clear-
ance. Although little is known about the chrono-pharmacokinetics
of this pathway, our hypothesis is supported by the fact that CAR,
which regulates expression of CYP2B6,21 exhibits a circadian rhythm
linked to a 1.7-fold magnitude induction of CYP2B mRNA.62
Despite the 29% amplitude of diurnal variation in nevirapine
clearance, the simulated difference between morning and even-
ing trough exposures was,15%. This lack of effect is due to nevir-
apine’s relatively long half-life (25–30 h at steady-state)41 in
18
0.6
0.8
1.0
1.2
1.4
19 20 21 22 23 24 1 2 3 4 5 6
Clock time (h)
Diurnal variation in nevirapine clearance
7 8 9 10 11 12 13 14 15 16 17 18
Figure 2. Diurnal variation in nevirapine intrinsic clearance detected by the model, presented over 24 h. The shaded area corresponds to night-time
(20.00–08.00 h).
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Figure 3. Change in nevirapine pre-hepatic bioavailability with age.
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comparison with, for example, PIs, where the reported median
difference in troughs is almost 60%.61 Simulations revealed only
a marginal effect of intake time on exposures, but showed that
the diurnal variation should be considered when the daily dose
of nevirapine cannot be split equally, since 50% difference in the
ratio of median Cmin AM/PM was found depending on whether the
larger dose is given in the morning or evening. To minimize this
effect and the risk of suboptimal exposures, uneven splitting
should be implemented with the larger dose given in the morning,
which is currently not specified in the WHO guidelines.35
A further innovation of our study was the use of a semi-
physiological well-stirred liver model, allowing the effect of hep-
atic clearance (expressed as intrinsic clearance) on both systemic
clearance and first-pass hepatic extraction to be captured, so that
clearance and its covariates affect bioavailability. This model
allowed us to separate the pre-hepatic and hepatic components
of bioavailability.
A significant degree of variability in nevirapine pharmacokinet-
ics was explained in our model by age-driven differences in pre-
hepatic bioavailability, which possibly overshadowed the
expected effect of maturation of the metabolic pathways. A simi-
lar effect was found for nevirapine by Foissac et al.13 and reported
for other antiretroviral drugs63 and could hypothetically be caused
by reduced drug absorption in neonates and younger children.
This may be due to more rapid gastric emptying, smaller gastric
volume, higher gastric pH, smaller gastrointestinal absorption
area, as well as adherence and palatability issues.64 This phenom-
enon could explain the subtherapeutic concentrations seen in the
youngest age groups in other paediatric studies.1,2,8 – 12 Our simu-
lations show in particular that individuals in the ,6 kg weight-
band who are EM and IM are at risk of suboptimal exposures
(observed evening Cmin ,3 mg/L in 43% and 26% of individuals,
respectively).
Despite significant differences in nevirapine pharmacokinetics
determined by CYP2B6 genotype, a genotype-driven dose opti-
mization strategy has not been previously suggested. This could
be due to the fact that, unlike efavirenz, the relationship between
high exposures and toxicity is not strongly apparent.7,16,65
Nonetheless, suboptimal concentrations are of concern, as they
could lead to virological failure.7 – 9,13 To prevent suboptimal expo-
sures we suggest the dose for EM and IM in the lowest weight-
band be increased from 100 to 150 mg. Further harmonization
of exposures across metabolizer groups could be achieved by
50% reduction of nevirapine dose for SM and USM in all other
weight-bands, as .75% of those children had evening Cmin
above the 8 mg/L therapeutic upper limit, although this might
be of limited clinical relevance. When the daily dose cannot be
split equally, larger doses should be given in the morning. The
simulated Cmin based on this dose-optimization approach are pre-
sented in Figure 4(c). We acknowledge, however, that practical
implementation of such a strategy in resource-limited settings
would be hindered by restricted access to genotyping and current
use of FDCs.
Our study has several limitations. The therapeutic range for
nevirapine used in our analysis has not been previously evaluated
in children or in African populations. The intake time for the sparse
pharmacokinetic data was self-reported and might be inaccurate,
given the large variability in absorption parameters, and could
inflate the magnitude of the detected diurnal variation. We tried
to minimize this effect by excluding samples with uncertain
dosage information and BLQ. The detected diurnal effect could
hypothetically be further affected by food intake, which was not
recorded in our study. However, food has been previously reported
not to modify nevirapine bioavailability or clearance.5 Additionally,
the analysed trials differed in the morning/evening dose-splitting
strategy (see the Methods section), but the model-based
approach we employed accounts for this difference.
Conclusions
This is the first study quantifying the combined effect of CYP2B6
516G.T|983T.C on nevirapine clearance in children and classify-
ing metabolizers into four metabolic groups (EM, IM, SM and USM).
To prevent subtherapeutic exposures, EM and IM children weigh-
ing ,6 kg should receive same the dose as those in the 6–10 kg
weight-band. Further homogenization of exposures can be
achieved by reducing the current recommended dose for SM
and USM by 50% in other weight-bands. Additionally, we charac-
terized the effect of diurnal variation on nevirapine pharmacokin-
etics, and found that it is of limited clinical relevance, possibly due
to nevirapine’s long half-life. However, this phenomenon should
be taken into consideration when daily doses cannot be split
equally and larger doses should be given in the morning.
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